<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-OK9SXZHX/eb75221f-577a-4d93-b8fd-6c622ff98868/HTML"><dcterms:extent>21 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-OK9SXZHX/70e5f17a-1871-4f45-a479-8a21b423ee45/PDF"><dcterms:extent>78 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-OK9SXZHX/aa21530e-d6e2-4d16-8c1c-30db2f1fec1f/TEXT"><dcterms:extent>18 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1929-2026"><edm:begin xml:lang="en">1929</edm:begin><edm:end xml:lang="en">2026</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-OK9SXZHX"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp" /><dcterms:issued>2010</dcterms:issued><dc:creator>Ihan, Alojz</dc:creator><dc:creator>Jeverica, Samo</dc:creator><dc:creator>Skvarč, Miha</dc:creator><dc:creator>Tepeš, Bojan</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:79</dc:format><dc:format xml:lang="sl">str. 25-30</dc:format><dc:identifier>ISSN:1318-0347</dc:identifier><dc:identifier>COBISSID:26668249</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-OK9SXZHX</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko zdravniško društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Zdravniški vestnik</dcterms:isPartOf><dc:subject xml:lang="en">antibiotic</dc:subject><dc:subject xml:lang="sl">antibiotiki</dc:subject><dc:subject xml:lang="en">bacteria</dc:subject><dc:subject xml:lang="sl">bakterije</dc:subject><dc:subject xml:lang="en">Clarithromycin</dc:subject><dc:subject xml:lang="en">Drug Resistance, Microbial</dc:subject><dc:subject xml:lang="en">Drug Therapy</dc:subject><dc:subject xml:lang="en">Helicobacter Infections</dc:subject><dc:subject xml:lang="en">Helicobacter Pylori</dc:subject><dc:subject xml:lang="en">Helicobacter, infekcije</dc:subject><dc:subject xml:lang="en">Immunology</dc:subject><dc:subject xml:lang="sl">Klaritromicin</dc:subject><dc:subject xml:lang="sl">Metronidazol</dc:subject><dc:subject xml:lang="en">Metronidazole</dc:subject><dc:subject xml:lang="en">Microbial Sensitivity Tests</dc:subject><dc:subject xml:lang="sl">Mikrobni, občutljivostni testi</dc:subject><dc:subject xml:lang="sl">odpornost</dc:subject><dc:subject xml:lang="sl">Zdravilo, rezistenca mikrobna</dc:subject><dcterms:temporal rdf:resource="1929-2026" /><dc:title xml:lang="sl">Primarna odpornost bakterije Helicobacter pylori| Primary resistance of Helicobacter pylori|</dc:title><dc:description xml:lang="sl">Background: Antimicrobial resistance, particularly against metronidazole and clarithromycin, is the leading cause for treatment failure of Helicobacter pylori infection. Eradication rates of primary therapy have fallen below 80% in the majority of states including Slovenia. Th e aim of the study was to assess primary resistance to key antibiotics used for eradication treatment. Patients and methods: Between 2007 and 2009 we isolated 97 strains of Helicobacter pylori from the treatment naive patients who have not previously underwent eradication treatment. Antimicrobial susceptibility testing was doneusing phenotypical methods. Etests and breakpoint agar dilution method formetronidazole. We analyzed resistance profi les of the isolated bacteria and presenteddistribution of different phenotypes of Helicobacter pylori. Results: Th e primary antimicrobial resistance for metronidazole and clarithromycin was 18.6% and 17.5%, respectively. Combined resistance for bothmetronidazole and clarithromycin was 4.1%. In our group of isolates we didnot fi nd any resistance against amoxicillin and tetracycline. 3.1% of isolates were ciprofl oxacin resistant. Conclusions: Systematic surveillance of antimicrobial resistance of Helicobacter pylori is mandatory to adjust primary and subsequent eradication therapy. Performing antimicrobial susceptibility testing is a costly method and that is why it is important to fi nd resources to make it possible</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-OK9SXZHX"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-OK9SXZHX" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-OK9SXZHX/70e5f17a-1871-4f45-a479-8a21b423ee45/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko zdravniško društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-OK9SXZHX/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-OK9SXZHX" /></ore:Aggregation></rdf:RDF>